Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III

Nov 08 2017

• By Mandy Jackson

microscope

Related Content

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m

Oct 30 2017

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

Apr 14 2017

Pipeline Watch: Phase III Readouts For Cabozantinib, Topical Glycopyrronium

Oct 23 2017

Corbus Cystic Fibrosis Data May Justify Longer, Larger Study

Mar 31 2017

AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats

Dec 23 2015

Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Dec 16 2016

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

Apr 26 2016

ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge

Nov 16 2016

Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All

Aug 30 2017

Duzallo Approval Opens Gout Opportunity For Ironwood

Aug 21 2017

Related Companies

Eli Lilly and Company

Incyte Corporation

AbbVie Inc.

Ironwood Pharmaceuticals, Inc.

AstraZeneca PLC

Corbus Pharmaceuticals Holdings, Inc.

University of Pennsylvania

Additional Topics

Business Strategies Clinical Trials Market Access Research & Development Immune Disorders BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window